MedPage Today’s year in review for inflammatory bowel disease
www.medpagetoday.com/gastroentero...
@medpagetoday.bsky.social
#GastroSky #IBDSky
www.medpagetoday.com/gastroentero...
@medpagetoday.bsky.social
#GastroSky #IBDSky
Year in Review: Inflammatory Bowel Disease
'Top down' vs 'step up' therapy, FDA actions, rethinking placebos, and new tulisokibart data
www.medpagetoday.com
November 23, 2024 at 1:06 PM
MedPage Today’s year in review for inflammatory bowel disease
www.medpagetoday.com/gastroentero...
@medpagetoday.bsky.social
#GastroSky #IBDSky
www.medpagetoday.com/gastroentero...
@medpagetoday.bsky.social
#GastroSky #IBDSky
News; ( NYSE: #LB ) Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
September 30, 2026 at 8:01 PM
Merck's Prometheus drug tulisokibart halved painful skin lesions in 72% of high-dose patients with hidradenitis suppurativa in a mid-stage study.
Merck shows off mid-stage win for Prometheus drug in painful skin disease
Merck's tulisokibart showed mid-stage success in hidradenitis suppurativa, with 72% high-dose patients seeing 50%+ abscess reduction vs 35% placebo at EADV congress.
endpoints.news
September 30, 2026 at 5:08 PM
Merck's Prometheus drug tulisokibart halved painful skin lesions in 72% of high-dose patients with hidradenitis suppurativa in a mid-stage study.
#$MRK tulisokibart met its Phase 2b HS goal and will move to Phase 3. H.C. Wainwright sees first anti-TL1A skin data as a class plus for #$STTK. notreload.xyz/xy/merck-hs-...
Merck HS Data Validates TL1A Path for Shattuck Labs
Merck’s tulisokibart met its Phase 2b HS goal and will move to Phase 3. H.C. Wainwright sees first anti-TL1A skin data as a class plus for Shattuck.
notreload.xyz
September 30, 2026 at 5:03 PM
#$MRK tulisokibart met its Phase 2b HS goal and will move to Phase 3. H.C. Wainwright sees first anti-TL1A skin data as a class plus for #$STTK. notreload.xyz/xy/merck-hs-...
APOLLO-CD
A phase 2a induction trial of tulisokibart, an anti-TL1A monoclonal antibody, shows promising efficacy & safety in patients with moderate-to-severe Crohn’s disease (CD) refractory to prior therapies.
Key findings from the APOLLO-CD study:
[🔗https://doi.org/10.1016/S2468-1253(25)00071-8]
A phase 2a induction trial of tulisokibart, an anti-TL1A monoclonal antibody, shows promising efficacy & safety in patients with moderate-to-severe Crohn’s disease (CD) refractory to prior therapies.
Key findings from the APOLLO-CD study:
[🔗https://doi.org/10.1016/S2468-1253(25)00071-8]
June 27, 2025 at 7:56 AM
APOLLO-CD
A phase 2a induction trial of tulisokibart, an anti-TL1A monoclonal antibody, shows promising efficacy & safety in patients with moderate-to-severe Crohn’s disease (CD) refractory to prior therapies.
Key findings from the APOLLO-CD study:
[🔗https://doi.org/10.1016/S2468-1253(25)00071-8]
A phase 2a induction trial of tulisokibart, an anti-TL1A monoclonal antibody, shows promising efficacy & safety in patients with moderate-to-severe Crohn’s disease (CD) refractory to prior therapies.
Key findings from the APOLLO-CD study:
[🔗https://doi.org/10.1016/S2468-1253(25)00071-8]
Novel Monoclonal Antibody Shows Promise in Ulcerative Colitis www.medpagetoday.com/gastroentero...
Novel Monoclonal Antibody Shows Promise in Ulcerative Colitis
26% of patients receiving tulisokibart achieved clinical remission vs 1% with placebo
www.medpagetoday.com
December 5, 2024 at 8:37 PM
Novel Monoclonal Antibody Shows Promise in Ulcerative Colitis www.medpagetoday.com/gastroentero...
#MSD's confidence in its anti-TL1A antibody tulisokibart in #inflammatorydiseases has been made apparent by a decision to start trials of the drug in three more indications.
MSD advances on a broad front with TL1A drug tulisokibart
MSD's confidence in its anti-TL1A drug tulisokibart in inflammatory diseases is made apparent by a decision to start trials in three new diseases.
buff.ly
October 7, 2025 at 3:30 PM
#MSD's confidence in its anti-TL1A antibody tulisokibart in #inflammatorydiseases has been made apparent by a decision to start trials of the drug in three more indications.
Linked Comment - James Lindsay - Tulisokibart shows promise for Crohn's disease
www.thelancet.com/journals/lan...
#gastrosky #ibdsky #medsky
www.thelancet.com/journals/lan...
#gastrosky #ibdsky #medsky
Tulisokibart shows promise for Crohn's disease
There have been important recent advances in the management of Crohn's disease, including
new classes of biological or small molecule therapies, an appreciation that endoscopic
mucosal healing results...
www.thelancet.com
May 31, 2025 at 4:27 PM
Linked Comment - James Lindsay - Tulisokibart shows promise for Crohn's disease
www.thelancet.com/journals/lan...
#gastrosky #ibdsky #medsky
www.thelancet.com/journals/lan...
#gastrosky #ibdsky #medsky
Merck & Co’s ‘pipeline in a product’ approach to tulisokibart continues as it moves the monoclonal antibody into three phase IIb clinical trials for immune-mediated inflammatory diseases
www.europeanpharmaceuticalreview.com/news/266817/...
#pharma #biologics
www.europeanpharmaceuticalreview.com/news/266817/...
#pharma #biologics
Merck & Co starts phase IIb study of tulisokibart in rheumatoid arthritis
The study is one of three to start, along with those in hidradenitis suppurativa and radiographic axial spondyloarthritis.
www.europeanpharmaceuticalreview.com
October 7, 2025 at 11:58 AM
Merck & Co’s ‘pipeline in a product’ approach to tulisokibart continues as it moves the monoclonal antibody into three phase IIb clinical trials for immune-mediated inflammatory diseases
www.europeanpharmaceuticalreview.com/news/266817/...
#pharma #biologics
www.europeanpharmaceuticalreview.com/news/266817/...
#pharma #biologics
Baricitinib,
Tocilizumab,
LITFULO,
Duvakitug, RG6631 (Roche)
Tulisokibart, les inhibiteurs de TYK2 (Brepocitinib, Deucravacitinib), les inhibiteurs de IRAK4, et d'autres sont à l'étude pour la dérégulation immunitaire du Covid Long.
Au vu de l'ampleur de l'impact du COVID Long,
Tocilizumab,
LITFULO,
Duvakitug, RG6631 (Roche)
Tulisokibart, les inhibiteurs de TYK2 (Brepocitinib, Deucravacitinib), les inhibiteurs de IRAK4, et d'autres sont à l'étude pour la dérégulation immunitaire du Covid Long.
Au vu de l'ampleur de l'impact du COVID Long,
July 28, 2025 at 1:49 PM
Baricitinib,
Tocilizumab,
LITFULO,
Duvakitug, RG6631 (Roche)
Tulisokibart, les inhibiteurs de TYK2 (Brepocitinib, Deucravacitinib), les inhibiteurs de IRAK4, et d'autres sont à l'étude pour la dérégulation immunitaire du Covid Long.
Au vu de l'ampleur de l'impact du COVID Long,
Tocilizumab,
LITFULO,
Duvakitug, RG6631 (Roche)
Tulisokibart, les inhibiteurs de TYK2 (Brepocitinib, Deucravacitinib), les inhibiteurs de IRAK4, et d'autres sont à l'étude pour la dérégulation immunitaire du Covid Long.
Au vu de l'ampleur de l'impact du COVID Long,
Why TL1A?
TL1A (TNFSF15) is a key driver of Th1/Th17-mediated inflammation and intestinal fibrosis—two critical components of CD pathogenesis.
Tulisokibart blocks TL1A from binding to its receptor DR3, dampening both inflammation and fibrotic signaling.
TL1A (TNFSF15) is a key driver of Th1/Th17-mediated inflammation and intestinal fibrosis—two critical components of CD pathogenesis.
Tulisokibart blocks TL1A from binding to its receptor DR3, dampening both inflammation and fibrotic signaling.
June 27, 2025 at 7:56 AM
Why TL1A?
TL1A (TNFSF15) is a key driver of Th1/Th17-mediated inflammation and intestinal fibrosis—two critical components of CD pathogenesis.
Tulisokibart blocks TL1A from binding to its receptor DR3, dampening both inflammation and fibrotic signaling.
TL1A (TNFSF15) is a key driver of Th1/Th17-mediated inflammation and intestinal fibrosis—two critical components of CD pathogenesis.
Tulisokibart blocks TL1A from binding to its receptor DR3, dampening both inflammation and fibrotic signaling.
Takeaway:
Tulisokibart appears safe and potentially efficacious in CD patients with high prior biologic exposure.
Early signals of both anti-inflammatory and anti-fibrotic activity suggest a dual mechanism worth watching.
A phase 3 trial is underway. 🧪
Tulisokibart appears safe and potentially efficacious in CD patients with high prior biologic exposure.
Early signals of both anti-inflammatory and anti-fibrotic activity suggest a dual mechanism worth watching.
A phase 3 trial is underway. 🧪
June 27, 2025 at 7:56 AM
Takeaway:
Tulisokibart appears safe and potentially efficacious in CD patients with high prior biologic exposure.
Early signals of both anti-inflammatory and anti-fibrotic activity suggest a dual mechanism worth watching.
A phase 3 trial is underway. 🧪
Tulisokibart appears safe and potentially efficacious in CD patients with high prior biologic exposure.
Early signals of both anti-inflammatory and anti-fibrotic activity suggest a dual mechanism worth watching.
A phase 3 trial is underway. 🧪
Induction therapy with tulisokibart in Crohn’s
At week 12, 13 (26%) of 50 patients had an endoscopic response in per-protocol analysis
Most frequent AEs: COVID-19 (6 [11%]), UTI (5 [9%]), Crohn's (5 [9%]), anaemia (4 [7%]), nasopharyngitis (3 [5%]), fatigue (3 [5%])
#gastrosky #medsky #ibdsky
At week 12, 13 (26%) of 50 patients had an endoscopic response in per-protocol analysis
Most frequent AEs: COVID-19 (6 [11%]), UTI (5 [9%]), Crohn's (5 [9%]), anaemia (4 [7%]), nasopharyngitis (3 [5%]), fatigue (3 [5%])
#gastrosky #medsky #ibdsky
New research - Feagan et al - Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
www.thelancet.com/journals/lan...
#gastrosky #medsky #ibdsky
www.thelancet.com/journals/lan...
#gastrosky #medsky #ibdsky
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
This proof-of-concept study showed that tulisokibart is potentially efficacious in
moderately to severely active Crohn's disease and is well tolerated. Randomised controlled
trials with longer duratio...
www.thelancet.com
June 1, 2025 at 6:17 AM
Induction therapy with tulisokibart in Crohn’s
At week 12, 13 (26%) of 50 patients had an endoscopic response in per-protocol analysis
Most frequent AEs: COVID-19 (6 [11%]), UTI (5 [9%]), Crohn's (5 [9%]), anaemia (4 [7%]), nasopharyngitis (3 [5%]), fatigue (3 [5%])
#gastrosky #medsky #ibdsky
At week 12, 13 (26%) of 50 patients had an endoscopic response in per-protocol analysis
Most frequent AEs: COVID-19 (6 [11%]), UTI (5 [9%]), Crohn's (5 [9%]), anaemia (4 [7%]), nasopharyngitis (3 [5%]), fatigue (3 [5%])
#gastrosky #medsky #ibdsky
8 IBD studies this week. The one that matters: tulisokibart hit Phase 3 in UC — first anti-TL1A to do it. New mechanism for people who've cycled through existing options. https://ibdmovement.com/week-of-june-22-28-2026-eight-ibd-research-stories-worth-reading/?utm_source=bluesky
June 29, 2026 at 2:11 PM
8 IBD studies this week. The one that matters: tulisokibart hit Phase 3 in UC — first anti-TL1A to do it. New mechanism for people who've cycled through existing options. https://ibdmovement.com/week-of-june-22-28-2026-eight-ibd-research-stories-worth-reading/?utm_source=bluesky
🧪 BREAKING: MSD's Tulisokibart (IL-23p19) hits Phase 3 endpoints in UC ATLAS study. New hope after anti-TNF/JAK/S1P failures.
Recruiting: NCT06617858 (Houston), NCT07128355 (Boston), NCT07258771 (Ann Arbor) → corterve.com/trials
#ClinicalTrials #UlcerativeColitis #IBD #Corterve
Recruiting: NCT06617858 (Houston), NCT07128355 (Boston), NCT07258771 (Ann Arbor) → corterve.com/trials
#ClinicalTrials #UlcerativeColitis #IBD #Corterve
August 24, 2026 at 11:17 AM
🧪 BREAKING: MSD's Tulisokibart (IL-23p19) hits Phase 3 endpoints in UC ATLAS study. New hope after anti-TNF/JAK/S1P failures.
Recruiting: NCT06617858 (Houston), NCT07128355 (Boston), NCT07258771 (Ann Arbor) → corterve.com/trials
#ClinicalTrials #UlcerativeColitis #IBD #Corterve
Recruiting: NCT06617858 (Houston), NCT07128355 (Boston), NCT07258771 (Ann Arbor) → corterve.com/trials
#ClinicalTrials #UlcerativeColitis #IBD #Corterve
#MSD's anti-TL1A antibody tulisokibart was effective in a phase 2 trial in skin disorder hidradenitis suppurativa, but failed a study in rare lung disorder SSc-ILD.
pharmaphorum.com/news/msd-rec...
pharmaphorum.com/news/msd-rec...
MSD records one win, one miss with TL1A drug tulisokibart
MSD's tulisokibart was effective in a phase 2 trial in skin disorder hidradenitis suppurativa, but has failed a study in rare lung disorder SSc-ILD.
pharmaphorum.com
August 4, 2026 at 12:54 PM
#MSD's anti-TL1A antibody tulisokibart was effective in a phase 2 trial in skin disorder hidradenitis suppurativa, but failed a study in rare lung disorder SSc-ILD.
pharmaphorum.com/news/msd-rec...
pharmaphorum.com/news/msd-rec...
#MSD's #tulisokibart has become the first anti-TL1A #antibody to help patients with a type of #inflammatoryboweldisease (IBD) achieve clinical #remission in a phase 3 trial.
buff.ly/8KAfDwW
buff.ly/8KAfDwW
June 23, 2026 at 12:00 PM
#MSD's #tulisokibart has become the first anti-TL1A #antibody to help patients with a type of #inflammatoryboweldisease (IBD) achieve clinical #remission in a phase 3 trial.
buff.ly/8KAfDwW
buff.ly/8KAfDwW
Boletim de MR sobre medicina, pesquisa, inovação, saúde mental, negócios e políticas públicas
www.moneyreport.com.br/saude-brasil...
www.moneyreport.com.br/saude-brasil...
Estamos enlouquecendo; insulina semanal; cura para o Mal de Crohn - Money Report
Boletim de MR sobre medicina, pesquisa, inovação, saúde mental, negócios e políticas públicas Nova droga pode aliviar doença de Crohn e colite ulcerativa Tulisokibart é o nome do novo medicamento imun...
www.moneyreport.com.br
March 17, 2025 at 1:48 PM
Boletim de MR sobre medicina, pesquisa, inovação, saúde mental, negócios e políticas públicas
www.moneyreport.com.br/saude-brasil...
www.moneyreport.com.br/saude-brasil...
Boletim de MR sobre medicina, pesquisa, inovação, saúde mental, negócios e políticas públicas
www.moneyreport.com.br/saude-brasil...
www.moneyreport.com.br/saude-brasil...
Estamos enlouquecendo; insulina semanal; cura para o Mal de Crohn - Money Report
Boletim de MR sobre medicina, pesquisa, inovação, saúde mental, negócios e políticas públicas Nova droga pode aliviar doença de Crohn e colite ulcerativa Tulisokibart é o nome do novo medicamento imun...
www.moneyreport.com.br
March 16, 2025 at 11:45 PM
Boletim de MR sobre medicina, pesquisa, inovação, saúde mental, negócios e políticas públicas
www.moneyreport.com.br/saude-brasil...
www.moneyreport.com.br/saude-brasil...
New research - Feagan et al - Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
www.thelancet.com/journals/lan...
#gastrosky #medsky #ibdsky
www.thelancet.com/journals/lan...
#gastrosky #medsky #ibdsky
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
This proof-of-concept study showed that tulisokibart is potentially efficacious in
moderately to severely active Crohn's disease and is well tolerated. Randomised controlled
trials with longer duratio...
www.thelancet.com
May 31, 2025 at 4:27 PM
New research - Feagan et al - Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
www.thelancet.com/journals/lan...
#gastrosky #medsky #ibdsky
www.thelancet.com/journals/lan...
#gastrosky #medsky #ibdsky
Tulisokibart firmy Merck osiąga główny cel w badaniu fazy 3 nad wrzodziejącym zapaleniem jelita grubego. ipharmacenter.com/post/merck-a...
#Merck #Tulisokibart #BadaniaKliniczne #Pharma #aktualności
#Merck #Tulisokibart #BadaniaKliniczne #Pharma #aktualności
Merck Advances Pipeline with Tulisokibart Phase 3 Data and EU Nod for Keytruda-Padcev | iPharmaCenter
Merck has announced pivotal advancements across its pipeline, highlighting positive Phase 3 data for its ulcerative colitis candidate, tulisokibart, alongside a fresh European approval for its Keytrud...
ipharmacenter.com
June 24, 2026 at 4:14 PM
Tulisokibart firmy Merck osiąga główny cel w badaniu fazy 3 nad wrzodziejącym zapaleniem jelita grubego. ipharmacenter.com/post/merck-a...
#Merck #Tulisokibart #BadaniaKliniczne #Pharma #aktualności
#Merck #Tulisokibart #BadaniaKliniczne #Pharma #aktualności
Tulisokibart van Merck behaalt primair eindpunt in Fase 3-studie naar colitis ulcerosa. ipharmacenter.com/post/merck-a...
#Merck #Tulisokibart #ColitisUlcerosa #KlinischeStudies #Pharma #Innovatie #nieuws
#Merck #Tulisokibart #ColitisUlcerosa #KlinischeStudies #Pharma #Innovatie #nieuws
Merck Advances Pipeline with Tulisokibart Phase 3 Data and EU Nod for Keytruda-Padcev | iPharmaCenter
Merck has announced pivotal advancements across its pipeline, highlighting positive Phase 3 data for its ulcerative colitis candidate, tulisokibart, alongside a fresh European approval for its Keytrud...
ipharmacenter.com
June 24, 2026 at 4:13 PM
Tulisokibart van Merck behaalt primair eindpunt in Fase 3-studie naar colitis ulcerosa. ipharmacenter.com/post/merck-a...
#Merck #Tulisokibart #ColitisUlcerosa #KlinischeStudies #Pharma #Innovatie #nieuws
#Merck #Tulisokibart #ColitisUlcerosa #KlinischeStudies #Pharma #Innovatie #nieuws
Tulisokibart da Merck atinge o objetivo primário no ensaio de Fase 3 para colite ulcerosa. ipharmacenter.com/post/merck-a...
#Merck #Tulisokibart #ColiteUlcerosa #EnsaiosClinicos #Pharma #Inovacao #notícias
#Merck #Tulisokibart #ColiteUlcerosa #EnsaiosClinicos #Pharma #Inovacao #notícias
Merck Advances Pipeline with Tulisokibart Phase 3 Data and EU Nod for Keytruda-Padcev | iPharmaCenter
Merck has announced pivotal advancements across its pipeline, highlighting positive Phase 3 data for its ulcerative colitis candidate, tulisokibart, alongside a fresh European approval for its Keytrud...
ipharmacenter.com
June 24, 2026 at 4:13 PM
Tulisokibart da Merck atinge o objetivo primário no ensaio de Fase 3 para colite ulcerosa. ipharmacenter.com/post/merck-a...
#Merck #Tulisokibart #ColiteUlcerosa #EnsaiosClinicos #Pharma #Inovacao #notícias
#Merck #Tulisokibart #ColiteUlcerosa #EnsaiosClinicos #Pharma #Inovacao #notícias